SCHEMBL3113014

SCHEMBL3113014

NNc1ccc(S(N)(=O)=O)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.60
GAA P10253 5/20 0.60
MAPT P10636 2/20 0.60
TDP1 Q9NUW8 2/20 0.58
MEN1 O00255 1/20 0.58
LMNA P02545 1/20 0.58
KMT2A Q03164 1/20 0.58
CA2 P00918 11/20 0.50
CA9 Q16790 9/20 0.50
CA1 P00915 9/20 0.50
CA12 O43570 5/20 0.50
CA4 P22748 3/20 0.50
CA6 P23280 2/20 0.50
CA5A P35218 2/20 0.50
CA7 P43166 2/20 0.50
CA14 Q9ULX7 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30096885 1.00 KDM4E (0.60) KDM4EGAAMAPTTDP1MEN1
Hydrochloric Acid SCHEMBL6313774 0.98 KDM4E (0.58) KDM4EGAAMAPTTDP1MEN1
SCHEMBL2571476 0.82 KDM4E (0.63) KDM4EGAAMAPTTDP1MEN1
SCHEMBL30088531 0.82 KDM4E (0.63) KDM4EGAAMAPTTDP1MEN1
SCHEMBL31028775 0.82 CA2 (0.52) KDM4EGAAMAPTTDP1MEN1
Hydrochloric Acid SCHEMBL5201544 0.81 KDM4E (0.61) KDM4EGAAMAPTTDP1MEN1
SCHEMBL23833646 0.79 KDM4E (0.59) KDM4EGAAMAPTTDP1MEN1
SCHEMBL23833584 0.79 GAA (0.59) KDM4EGAAMAPTTDP1MEN1
SCHEMBL2565104 0.78 KDM4E (0.71) KDM4EGAAMAPTTDP1MEN1
SCHEMBL2570550 0.78 KDM4E (0.55) KDM4EGAAMAPTTDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115605467-B PHD inhibitor compounds, compositions and uses thereof 阿克比治疗有限公司 2025-06-13 CN disclosed
CN-120004851-A PHD inhibitor compounds, compositions and uses thereof 阿克比治疗有限公司 2025-05-16 CN disclosed
US-20230212138-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE AKEBIA THERAPEUTICS, INC. (US) 2023-07-06 US disclosed
US-20230212138-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE AKEBIA THERAPEUTICS, INC. (US) 2023-07-06 US disclosed
US-20230212138-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE AKEBIA THERAPEUTICS, INC. (US) 2023-07-06 US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121424-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE Akebia Therapeutics Inc. (US) 2023-01-25 EP disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 EP disclosed
US-20030007927-A1 Radiopharmaceuticals for imaging infection and inflammation BARRETT JOHN A (US) 2003-01-09 US disclosed
US-20030003049-A1 Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation LANTHEUS MEDICAL IMAGING, INC. 2003-01-02 US disclosed
US-6416733-B1 RADIOPHARMACEUTICALS BIND IN VIVO TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR ON THE SURFACE OF LEUKOCYTES WHICH ACCUMULATE AT THE SITE OF INFECTION AND INFLAMMATION BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-07-09 US disclosed
WO-2002036173-A2 SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-05-10 WO disclosed
EP-0999856-A2 RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION Du Pont Pharmaceuticals Company (US) 2000-05-17 EP disclosed
CN-1239895-A Radiopharmaceuticals for imaging sites of infection and inflammation DU PONT MERCK PHARMA (US) 1999-12-29 CN disclosed
WO-1998015295-A2 RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION DUPONT PHARMACEUTICALS COMPANY (US) 1998-04-16 WO disclosed
US-4273706-A Nondiffusible heterocyclylazonaphthol dye-releasing compounds EASTMAN KODAK COMPANY (US) 1981-06-16 US disclosed
US-4207104-A DIFFUSION TRANSFER TO FORM METALLIZED DYE IMAGE OF EXCELLENT STABILITY EASTMAN KODAK COMPANY (US) 1980-06-10 US disclosed
US-4204870-A METALLIZED DYES EASTMAN KODAK COMPANY (US) 1980-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030007927-A1 Radiopharmaceuticals for imaging infection and inflammation LTB4R, LTB4R2, LTA4H KDM4E 4406/4885GAA 3359/4885MAPT 4656/4885
US-20230212138-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE HIF1AN, EGLN3, EGLN2 KDM4E 76/4885GAA 3664/4885MAPT 4584/4885
US-20030003049-A1 Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation LTB4R, LTB4R2, FABP3 KDM4E 4805/4885GAA 4427/4885MAPT 4682/4885
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 KDM4E 69/4885GAA 3851/4885MAPT 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.